On the stock market since 2020, it operates in the world of health and science. It has 507 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
The cash pile is strong; debt and other items pull the grade toward the middle.
Clearly below the class average.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Growth: Sales growth trails the sector average.
Business Quality: Profit power and business quality trail similar companies in the sector.
The stock trades 52% below its peak. The market has trimmed its expectations for the company.
There is $1.6B in the vault; even if every debt were paid off, $1.3B would remain.
The average analyst price target is $89.00 — 58% above today’s price.
A loss of $766.6M against $0 in annual sales.
At the current pace of spending, the cash lasts about 2 years. After that, the company needs to find new money.
On our five-subject report card, PCVX sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: PCVX is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Analysts’ average target sits above today’s price, yet the valuation grade (48/100) says the stock isn’t cheap.